Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
The sponsor’s research activity is centered on advanced and recurrent ovarian cancer, including platinum-sensitive recurrent disease, poor-prognosis ovarian cancer, and cancers of the tubal and peritoneal origin. Its funded studies also address treatment after surgery and maintenance strategies in patients with residual risk of relapse.
- Maintenance therapy in recurrent ovarian cancer
- Platinum-sensitive recurrence
- Advanced ovarian, tubal, and peritoneal cancer
- Poor prognostic ovarian cancer
Research in this area reflects a strong focus on chemotherapy combinations, anti-angiogenic treatment, PARP inhibition, and immunotherapy for ovarian malignancies.
Endometrial Cancer and Mismatch Repair Deficiency
The sponsor supports studies in advanced and metastatic endometrial cancer, with particular attention to tumors with MMR deficiency. Its trial portfolio also includes patients with endometrial carcinosarcoma, reflecting interest in aggressive uterine malignancies with limited treatment options.
- MMR-deficient endometrial cancer
- Advanced metastatic endometrial disease
- Endometrial carcinosarcoma
- Immunotherapy-based treatment strategies
These studies emphasize immune checkpoint blockade and combination approaches in biologically defined endometrial cancer populations.
Cervical Cancer
The sponsor is also active in locally advanced cervical cancer, with research focused on cervical squamous carcinoma and adenosquamous carcinoma in patients without metastatic disease. This area includes interest in treatment-naive disease requiring definitive systemic and local management.
- Locally advanced cervical cancer
- Squamous and adenosquamous histology
- Non-metastatic disease
- Immune-based combinations
The research profile in this field highlights immunotherapy combinations for cervical tumors with advanced local extent.
Ovarian Small Cell Carcinoma
The sponsor funds research in the rare setting of ovarian small cell carcinoma, including the hypercalcemic type. This area represents a distinct therapeutic interest in uncommon gynecologic malignancies with highly specialized treatment needs.
- Small cell ovarian carcinoma
- Hypercalcemic type
- Rare gynecologic cancer
- Chemo-immunotherapy
Studies in this domain explore platinum-based chemotherapy alongside immune checkpoint inhibitors in a rare ovarian cancer subtype.
